Nuvalent, Inc. NUVL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct Expenses Related To Program by Product | ||||||
| Discovery Programs | $12.55M+36.2% | $11.88M+29.4% | $11.38M+29.6% | $10.18M+15.1% | $9.21M+7.9% | |
| Neladalkib | $103.76M+20.6% | $105.45M+55.6% | $109.43M+108% | $100.16M+151% | $86.05M+156% | |
| NVL-330 | $24.68M+140% | $21.82M+163% | $19.1M+142% | $14.47M+60.3% | $10.28M+3.4% | |
| Zidesamtinib | $56.28M-16.4% | $59.52M-4.2% | $68.21M+35.4% | $69.69M+77.8% | $67.3M+115% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Nuvalent, Inc. break its business down?
- Nuvalent, Inc. (NUVL) reports direct expenses related to program by product across 4 parts — Discovery Programs, Neladalkib, NVL-330 and Zidesamtinib. Each is extracted from the segment footnotes and tracked over time.
- Where does Nuvalent, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Nuvalent, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.